Table 1.
Summary of engineering methods of biomembranes and introduced additional functions
| Source cells | Inherent functions | Engineering methods | Introduced additional functions | Particle size (nm) | References |
|---|---|---|---|---|---|
| Red blood cells | Prolong blood circulation time; Abnormal RBCs can target the mononuclear macrophage system. |
Postinsertion method | Enhance targeting ability | 75-200 | 52,73-76 |
| Cross physiological barriers | |||||
| T cells | Avoid being cleared by the immune system; Target tumor sites. |
Metabolic engineering | Enhance targeting ability | 75 | 82 |
| Macrophage cells | Avoid being cleared by the immune system; Target inflammatory or tumor sites. |
Postinsertion method | Cross physiological barriers; Enhance targeting ability |
123 | 29 |
| Neutrophil cells | Avoid being cleared by the immune system; Extravasate across inflamed endothelial layer. |
Chemical method | Enhance targeting ability | 70 | 85 |
| Dendritic cells | Avoid being cleared by the immune system; Present antigens to stimulate an immune response. |
Metabolic engineering | Link immune-stimulatory ligands | 240 | 87 |
| Cancer cells | Prolong blood circulation time; Homotypic targeting capability; Present antigens to stimulate an immune response. |
Gene engineering | Enhance targeting ability; Cross physiological barriers; Link therapeutic ligands |
84-175 | 34, 91-93 |
| Postinsertion method | |||||
| Metabolic engineering | |||||
| Platelets | Prolong blood circulation time; Target damaged vasculature; Target pathogenic bacteria and cancer cells. |
Chemical method; Postinsertion method |
Link therapeutic ligands; Enhance targeting ability |
106-122 | 100-101 |
| Exosomes | The contents are inherited from the source cells; Certain types of exosomes can cross the blood-brain barrier. |
Chemical method | Enhance targeting ability; Prolong blood circulation |
113-143 | 38, 112-113, 115-116 |
| Gene engineering | |||||
| Postinsertion method |